Zhejiang Qimei Cosmetics drew an FDA warning for CGMP violations in sterile-labeled OTC isopropyl alcohol prep pads.
What happened
FDA reviewed records the company submitted after its March 11, 2024 request under section 704(a)(4) of the FD&C Act. FDA found the quality unit did not show the sterile-labeled OTC IPA prep pads were made by a process adequate to render them sterile, did not test finished batches for IPA identity and strength before release, and did not test incoming components for identity and hazardous impurities.
What FDA found
The quality control unit did not ensure that OTC IPA prep pads labeled sterile were made by a process shown to render them sterile.
21 CFR 211.22The firm did not test each finished batch for identity and strength of the active ingredient IPA before release.
21 CFR 211.165(a)The firm did not test incoming glycerin, propylene glycol, ethanol, and IPA for identity and hazardous impurities such as DEG/EG or methanol as required.
21 CFR 211.84(d)(1)
What FDA wants
FDA tells the company to correct the violations promptly and respond in writing within 15 working days with actions taken and steps to prevent recurrence; it also recommends a qualified CGMP consultant and a six-system audit.
Who should pay attention
- brands that buy OTC drug products from this contract manufacturer
- distributors and importers of sterile-labeled prep pads
- drugmakers using glycerin, propylene glycol, ethanol, or IPA components
This is a summary. Read the original letter on fda.gov.